Lung cancer is still the top cancer killer, but new developments are shifting what the future might hold for patients.
3d
Study identifies two factors that may help patients benefit from off-the-shelf CAR T-cell therapies
Researchers at The University of Texas MD Anderson Cancer Center have traced how off-the-shelf chimeric antigen receptor (CAR ...
GLP-1 drugs like Ozempic and Wegovy may lower cancer risk by altering the body's immune response, but researchers say key ...
For patients with early-stage lung cancer who cannot undergo surgery, precision radiation therapy is the main curative-intent ...
UCLA investigators present the latest radiotherapy research at the American Society for Radiation Oncology annual meeting ...
The addition of CDK4/6 inhibitors to endocrine therapy has changed the standard of care for patients with high-risk, ...
Conversations about cancer research are tough for anyone who has ever been diagnosed, treated, or lost someone to the disease ...
Approved CD20×CD3 bispecifics (epcoritamab, glofitamab, mosunetuzumab) deliver meaningful ORR/CR in heavily pretreated DLBCL, but PFS remains modest, motivating combination strategies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results